The potential
implications for development of an effective vaccine against T. solium
infection seemed obvious. However the logic of this approach
was less than obvious to others and publication of the speculative
article in 1999 was intended to raise the stakes. The logical potential
for development and use of a vaccine to contribute to T. solium
control was not obvious to the assessors of a funding application to
the National Institutes of Health (NIH), the assessment of which intoned
that nothing more than praziquantel is needed for the control
of neurocysticercosis